Skip to main navigation
Skip to search
Skip to main content
University of Birmingham Home
Help & FAQ
Link opens in a new tab
Search content at University of Birmingham
Home
Research output
Profiles
Research units
Projects
Activities
Datasets
Equipment
Prizes
Press/Media
Dopamine Agonist Monotherapy in Parkinson's Disease
Carl Clarke
, M Guttman
Research output
:
Contribution to journal
›
Article
96
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Dopamine Agonist Monotherapy in Parkinson's Disease'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Monotherapy
100%
Parkinson's Disease
100%
Dopamine Agonist
100%
Levodopa
100%
Single-photon Emission Computed Tomography (SPECT)
36%
Pramipexole
27%
Young Patients
18%
Striatal
18%
Positron Emission Tomography
18%
Dopaminergic Neurons
18%
Motor Impairment
18%
Involuntary Movement
18%
Loss Reduction
18%
Dementia
9%
Clinical Trials
9%
Health Economics
9%
Comorbidity
9%
Randomized Controlled Trial
9%
Adverse Events
9%
Number of Patients
9%
Surrogate Marker
9%
Initial Treatment
9%
High Incidence
9%
Neuroprotective
9%
Differential Effects
9%
Health-related Quality of Life
9%
Life Data
9%
Motor Complications
9%
Response Fluctuations
9%
Pragmatic Trial
9%
Early Parkinson's Disease
9%
Selegiline
9%
Imaging Outcome Measures
9%
Low Quality Data
9%
Neuroprotectant
9%
Long-term Treatment
9%
β-CIT
9%
Motor Function
9%
Neurology
9%
123I
9%
Parkinson
9%
Slow Progressor
9%
Ropinirole
9%
Disease Management
9%
Short Life Expectancy
9%
18F-DOPA
9%
Dopamine Transporter
9%
Economic Statistics
9%
Pharmacology, Toxicology and Pharmaceutical Science
Monotherapy
100%
Dopamine Receptor Stimulating Agent
100%
Parkinson's Disease
100%
Levodopa
100%
Pramipexole
27%
Motor Dysfunction
18%
Clinical Trial
9%
Randomized Controlled Trial
9%
Adverse Event
9%
Disease Marker
9%
Neuroprotective Agent
9%
Tracer
9%
Selegiline
9%
Life Expectancy
9%
Computed Tomography Studies
9%
Fluorine 18
9%
Ropinirole
9%
Comorbidity
9%
Iodine-123
9%
Dopamine Transporter
9%
DOPA
9%
Diseases
9%
Neuroscience
Parkinson's Disease
100%
Dopamine Agonist
100%
L-DOPA
100%
Agonist
54%
Single-Photon Emission Computed Tomography
36%
Pramipexole
27%
positron emission tomographic scan
18%
Dopaminergic Neuron
18%
Stereotypic Movement Disorder
18%
Neuroprotective Agent
9%
Randomized Controlled Trial
9%
Selegiline
9%
Fluorine-18
9%
Dopamine Transporter
9%
Iodine-123
9%
Comorbidity
9%
Dopaminergic
9%
DOPA
9%
Ropinirole
9%